Pharmaceutical industry trade groups commonly claim that growing revenues (supported by premium prices) are required to drive innovative R&D, whereas critics maintain that drug companies' outsized returns mainly support corporate infrastructures, fuel marketing budgets and enrich investors. In fact, both arguments are incompletely supported by

中文翻译：

---

市场观察：制药公司研发支出趋势：2005–2015

制药行业贸易团体通常声称，要推动创新的研发，就需要增加收入（由溢价支撑），而批评家则认为，制药公司的超额收益主要是支持企业基础设施，燃料营销预算和丰富投资者。实际上，这两个论点都没有得到以下方面的完全支持